INSM vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 02, 2026

INSM

47.1
AI Score
VS
MRNA Wins

MRNA

51.3
AI Score

Investment Advisor Scores

INSM

47score
Recommendation
HOLD

MRNA

51score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric INSM MRNA Winner
Revenue 534.00M 305.96M MRNA
Net Income -2.13B -163.56M INSM
Net Margin -397.9% -53.5% INSM
Operating Income -2.20B -153.32M INSM
ROE -31.4% -23.2% INSM
ROA -19.4% -7.9% INSM
Total Assets 10.96B 2.08B MRNA
Cash 1.72B 582.19M MRNA
Debt/Equity 0.09 0.78 MRNA
Current Ratio 2.29 4.47 INSM
Free Cash Flow -1.25B -226.22M INSM

Relative Price Performance (Last 90 Days)

INSM 1M: +11.4% · 3M: +25.5% MRNA 1M: -23.7% · 3M: +20.3%

Current Technical Phase

INSM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 74

RSI (14): 74.3 · Price: $131.74

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 49

RSI (14): 49.0 · Price: $58.39

Fundamentals Snapshot

Metric INSM MRNA
Market Cap
Forward P/E 838.8 -11.0
Trailing P/E
Revenue (TTM)
Revenue Growth 2.3% 0.0%
Gross Margin 0.8% -0.7%
Operating Margin -0.7% -5.6%
EPS -5.76 -7.88
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.